Pet News

A recent study investigating the health impacts of fresh, human-grade dog food compared to conventional kibble in older canines has come under scrutiny from BSM Partners. This metabolomic research, initially suggesting fresh food promotes healthier aging, faces significant challenges regarding its methodology, data accuracy, and overall conclusions. BSM Partners' detailed critique highlights several areas of concern, including the confounding variables in the study's design, mathematical inaccuracies in nutritional reporting, and a lack of transparency concerning crucial experimental details. These issues cast doubt on the initial findings and emphasize the importance of rigorous scientific standards in pet nutrition research.

The study, led by Dr. Heather Huson from Cornell University, in collaboration with veterinary nutritionists from The Farmer's Dog, aimed to assess how different diets influence the metabolic health of 22 senior dogs over a year. While the study concluded that fresh, minimally processed food could positively impact metabolic health and support longevity, BSM Partners' analysis suggests these conclusions might be flawed due to several critical issues.

One of the primary concerns raised by BSM Partners is the study's confounded design. The two diets—fresh food and kibble—differed not only in their processing methods but also significantly in their nutritional composition. The fresh food contained higher levels of protein and fat, substantially fewer carbohydrates, and added Omega-3 fatty acids, making it difficult to ascertain whether observed health outcomes were due to the processing method or the distinct nutrient profiles. Furthermore, the kibble used was an experimental diet, not reflective of commercially available products, which limits the applicability of the findings to real-world scenarios.

BSM Partners also identified what they describe as widespread mathematical errors within the study's nutrient tables. For example, vitamin A and copper levels were reportedly listed at concentrations far exceeding safe limits set by the Association of American Feed Control Officials (AAFCO), potentially posing toxicity risks to dogs. Similar discrepancies were found for other minerals like iron, zinc, and manganese, with reported levels being 50 to 100 times higher than AAFCO's minimum nutritional requirements.

Transparency in methodology was another key point of contention. BSM Partners noted that the study failed to provide essential details on how the diets were prepared, including cooking methods, durations, and temperatures. Information regarding food intake or consumption by the participating dogs was also omitted. Crucially, the research did not clarify whether nutrient levels were laboratory-tested or merely calculated, which is vital for data reliability. Additionally, some dogs received various medications during the study, yet the timing, dosages, and corresponding diets were not clearly documented, potentially interfering with blood chemistry results and confounding the study's outcomes.

The definition of 'fresh' food as presented in the study also sparked debate. BSM Partners argues that the test diet, being heat-cooked and packaged for safety and shelf stability, does not align with the FDA and AAFCO's definition of fresh, which typically refers to food in its raw state, preserved only by simple refrigeration. This misclassification further undermines the study's claims about the benefits of 'fresh' food.

Finally, BSM Partners expressed reservations about the peer-review process itself, suggesting that studies with significant flaws can sometimes be published, particularly in newer or less stringent journals. They highlighted that despite the systematic mathematical errors, confounded design, and missing methodological details, this study managed to pass peer review, indicating a potential lapse in the oversight process.

Revolutionizing Feline Health: A Breakthrough in Weight Management

Pioneering a Novel Approach to Feline Weight Management

Akston has officially begun a clinical study at Cornell University's College of Veterinary Medicine. This trial is set to evaluate a groundbreaking once-weekly GLP-1 therapy specifically formulated for managing weight in cats. The study will involve domestic cats with overweight conditions, observed over a period of approximately three months.

The Escalating Challenge of Feline Obesity

Statistics from the Association for Pet Obesity Prevention reveal a concerning trend: in 2022, nearly two-thirds of American cats were categorized as overweight or obese. A more recent survey in 2024 indicated that 33% of cat owners identified their pets as having weight issues, an increase from 28% in the previous year, highlighting the growing scale of this health concern.

Unveiling Akston's Innovative GLP-1 Therapy

The core of Akston's therapeutic strategy is a GLP-1 protein, meticulously engineered to assist cats in regulating their appetite. Prior preclinical investigations conducted at Cornell University, utilizing laboratory cats, demonstrated the therapy's safety, reporting no observed adverse reactions or unexpected incidents. Pharmacokinetic analysis further confirmed the suitability of a once-weekly dosage regimen for the treatment.

The Science Behind Extended Efficacy

This groundbreaking therapy is developed leveraging Akston's proprietary Fc-fusion protein platform. This advanced technological base enables the precise design, synthesis, and rigorous testing of therapeutics. A key advantage of this platform is its capacity to fine-tune interactions with the immune system, thereby extending the duration of the therapy's action and enhancing its effectiveness.

Addressing a Critical Unmet Need in Veterinary Medicine

Dr. Todd Zion, co-founder and CEO of Akston, emphasized the significant impact of feline obesity, noting it as one of the most prevalent yet inadequately treated health problems in veterinary practice. He stated that by advancing this once-weekly GLP-1 therapy, Akston is directly confronting a substantial unmet need, aspiring to improve cats' health and extend their lifespans.

Enrollment Underway: A Collaborative Effort for Future Pet Health

The clinical study is currently enrolling participants at Cornell University. Initially, the goal is to enlist 70 cats, with potential plans to expand enrollment to 140. Dr. Patrick Carney, Associate Professor of Clinical Sciences at Cornell University College of Veterinary Medicine, expressed his enthusiasm for the potential of this tool. He highlighted that it could represent a significant breakthrough for veterinarians by providing a safe and effective solution where none currently exists.

Expanding Horizons: GLP-1 Therapy for Canine Companions

Akston is not solely focused on feline health; the company is also developing a GLP-1 program for dogs. This canine-focused initiative is progressing approximately six months behind the feline program, indicating a broader commitment to addressing pet obesity across different species.